Stephen Basil Thomas - Jun 27, 2024 Form 4 Insider Report for Eliem Therapeutics, Inc. (ELYM)

Role
Director
Signature
/s/ Emily Pimblett, Attorney-in-Fact
Stock symbol
ELYM
Transactions as of
Jun 27, 2024
Transactions value $
$0
Form type
4
Date filed
6/27/2024, 07:03 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELYM Common Stock Award +104K 104K Jun 27, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELYM Restricted Stock Units Award $0 +100K $0.00 100K Jun 27, 2024 Common Stock 100K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person acquired 103,907 shares of the issuer's common stock in exchange for 838,000 shares of common stock of Tenet Medicines, Inc. ("Tenet") in connection with the issuer's acquisition of all of the outstanding common stock of Tenet on June 27, 2024 (the "Acquisition"). On the effective date of the Acquisition, the closing price of the issuer's common stock was $7.53 per share.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F3 The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.